PR Newswire Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization Formosa Pharmaceuticals Makes First Shipment...\n more…
Globe Newswire Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with...\n more…
Globe Newswire Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transitionNEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a...\n more…
Ticker Report Eyenovia, Inc. (NASDAQ:EYEN - Get Free Report) was the recipient of a significant increase in short interest in August. As of August 15th, there was short interest totalling 3,030,000 shares, an...\n more…
Ticker Report Eyenovia, Inc. (NASDAQ:EYEN - Get Free Report) CEO Michael M. Rowe bought 50,000 shares of the company's stock in a transaction that occurred on Monday, August 26th. The shares were bought at an...\n more…